Glucosamine Conjugated Gadolinium (III) Oxide Nanoparticles as a Novel Targeted Contrast Agent for Cancer Diagnosis in MRI

• Published in: Journal of biomedical physics and engineering Vol. 10; no. 1; pp. 25 - 38
• Main Authors: T, Mortezazadeh, E, Gholibegloo, N, Riyahi Alam, S, Haghgoo, A E, Musa, M, Khoobi
• Format: Journal Article
• Language: English
• Published: Iran Shiraz University of Medical Sciences 01.02.2020
• Subjects: contrast media; gadolinium; magnetic resonance imaging; Original; Magnetic Resonance Imaging; Gadolinium; Contrast media
• ISSN: 2251-7200; 2251-7200
• DOI: 10.31661/jbpe.v0i0.1018

Glucose transporter (Glut), a cellular transmembrane receptor, has a key role in the metabolism of cell glucose and is also associated with various human carcinomas. In this study, we evaluated a magnetic resonance (MR) imaging contrast agent for tumor detection based on paramagnetic gadolinium oxide (Gd O ) coated polycyclodextrin (PCD) and modified with glucose (Gd O @PCD-Glu) for the targeting of overexpressed glucose receptors. In this experimental study, 3T magnetic resonance imaging (MRI) scanner was used to assess the specific interactions between Glut1-overexpressing tumor cells (MDA-MB-231) and Gd O @PCD-Glu NPs. Furthermore, the capacity of transporting Gd O @PCD-Glu NPs to tumor cells was evaluated. It was found that the acquired MRI T signal intensity of MDA-MB-231 cells that were treated with the Gd O @PCD-Glu NPs increased significantly. Based on the results obtained, Gd O @PCD-Glu NPs can be applied in targeting Glut1-overexpressing tumor cells in vivo, as well as an MRI-targeted tumor agent to enhance tumor diagnosis. Results have shown that glucose-shell of magnetic nanoparticles has a key role in diagnosing cancer cells of high metabolic activity.